BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 07, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 2/4 cls
Amicus Therapeutics Inc. (NASDAQ:FOLD) Leerink Joseph Schwartz Upgrade Market outperform (from market perform) 13% $6.14
Schwartz raised his target to $8 from $4 after speaking with key opinion leaders about the Phase III trial of Amigal migalastat to treat Fabry's disease. He anticipates data in 4Q11. Schwartz sees the October deal granting GlaxoSmithKline plc (LSE:GSK; NSYE:GSK) exclusive, worldwide rights to Amigal as validation for the small molecule that enhances alpha galactosidase A activity (see BioCentury, Nov. 1, 2010).
BTG plc (LSE:BGC) Nomura Gary Waanders Upgrade Buy (from reduce) -3% 223.5p
Waanders raised his target to 280p-300p from 193p-203p after BTG completed its acquisition of Biocompatibles International plc. He thinks the acquisition strengthens BTG's financial and operational foundations and reduces its exposure to individual pipeline...

Read the full 909 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >